What BMI Do You Need for Wegovy in the UK?

In the UK, the BMI needed to access Wegovy depends on whether you are seeking treatment through the NHS or privately. For NHS treatment, NICE criteria generally require a BMI of 35 or higher plus at least one weight-related health condition. Some people may qualify at a lower BMI, and ethnic background can affect the thresholds used.

BMI is only one part of an assessment. A clinician will also consider your health, previous weight-management support, medicines, preferences, and whether treatment can be provided safely. Wegovy is not suitable for everyone, and meeting a BMI threshold does not automatically guarantee a prescription.

Quick answer: NHS eligibility for Wegovy

Under NICE guidance, semaglutide (the medicine in Wegovy) may be offered to adults through specialist weight-management services when the following criteria are met:

Your BMI is at least 35 kg/m², and you have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or obstructive sleep apnea.
Alternatively, your BMI may be between 30 and 34.9 kg/m² if you meet the criteria for referral to a specialist weight-management service.
Lower BMI thresholds may apply for people from some ethnic backgrounds, including South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds. NICE recommends reducing the relevant BMI threshold by 2.5 kg/m² for these groups.
Treatment is provided alongside a reduced-calorie diet and increased physical activity, with support from a specialist multidisciplinary team.

NICE recommends that Wegovy be used for a maximum of two years in this NHS specialist-service pathway. Local referral routes and service availability can vary, so your GP or local weight-management service can explain what applies in your area.

What is BMI, and how is it used?

Body mass index (BMI) is calculated by dividing weight in kilograms by height in meters squared. It is a simple screening measure, not a direct measurement of body fat or overall health. BMI does not distinguish between muscle and fat, and it cannot show where body fat is carried.

Clinicians may use BMI alongside other information, such as waist measurement, blood pressure, blood tests, health history, and the effect of weight on daily life. It is best viewed as one measure in a broader assessment—not a judgment about someone’s effort or character.

What are the NICE criteria for Wegovy?

NICE (the National Institute for Health and Care Excellence) assesses medicines for use in the NHS. Its recommendation for semaglutide is narrower than the product’s potential use in private care, because NHS treatment has specific eligibility, service, and duration requirements.

Route Typical BMI threshold Other considerations NHS, under NICE guidance Usually 35 kg/m² or higher At least one weight-related condition; treatment through a specialist weight-management service. Lower thresholds may apply for some ethnic backgrounds. NHS, lower BMI pathway 30–34.9 kg/m² may be considered You must meet local criteria for referral to a specialist weight-management service. Eligibility is not automatic. Private prescribing May differ from the NHS pathway A qualified prescriber must assess whether treatment is appropriate and follow the licensed product information and professional standards.

For people from ethnic groups for whom health risks can arise at a lower BMI, NICE’s adjustment is intended to reflect that risk. The adjustment is not a separate guarantee of access: the relevant clinical and service criteria still need to be considered.

What counts as a weight-related condition?

Examples can include type 2 diabetes, high blood pressure, abnormal blood lipids, obstructive sleep apnea, cardiovascular disease, or other conditions that a clinician considers linked to excess weight. The specific condition and its relevance are assessed in context. Simply having a BMI above a threshold may not be enough for NHS treatment.

What is a specialist service?

A specialist service is a structured weight-management program with a multidisciplinary team. Depending on the service, this may include doctors, nurses, dietitians, psychologists, and other trained professionals. The team can review health risks, support nutrition and activity changes, monitor treatment, and help address barriers to long-term progress.

NICE’s NHS recommendation places Wegovy within this type of service rather than treating the medicine as a stand-alone solution. If you are interested, speak with your GP about referral options. Access and waiting times differ across the UK, and not every area offers the same pathway.

How do GLP-1 receptor agonists work?

Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone involved in appetite and blood-sugar regulation. Semaglutide acts on GLP-1 receptors, helping many people feel fuller after eating, reducing hunger, and making it easier to eat smaller portions. It also slows stomach emptying, particularly early in treatment.

The medicine is given as a once-weekly injection, with the dose usually increased gradually under medical supervision. Gradual dose escalation can help the body adjust and may reduce gastrointestinal side effects. The dose should not be changed without advice from the prescriber.

Wegovy and Ozempic both contain semaglutide, but they are not interchangeable brands for every purpose. Wegovy is licensed in the UK for weight management in eligible people, alongside lifestyle support. Ozempic is a brand used for type 2 diabetes. A prescription for one brand should not be assumed to authorize use of the other, and treatment should be based on a clinician’s assessment.

What do the STEP trials and other RCTs show?

The STEP program includes randomized controlled trials (RCTs) that studied semaglutide for weight management. RCTs compare a treatment with a control—often a placebo—while participants receive structured support. These studies provide strong evidence about average outcomes, but they cannot predict exactly how one individual will respond.

STEP 1: In adults with overweight or obesity without diabetes, participants receiving semaglutide alongside lifestyle intervention lost an average of about 14.9% of their starting weight over 68 weeks. The placebo group lost about 2.4% on average.
STEP 2: In adults with type 2 diabetes and overweight or obesity, average weight loss with semaglutide was lower than in STEP 1, but greater than with placebo.
STEP 4: This trial examined continued treatment after an initial semaglutide period. People who continued treatment generally maintained or increased weight loss, while those switched to placebo regained some weight on average.
STEP 5: Over 104 weeks, results showed that clinically meaningful weight loss could be sustained for many participants while treatment continued alongside lifestyle support.

These trials show that semaglutide can be effective for weight management, but responses vary. The studies also underline that ongoing support matters. Weight regain can occur after stopping treatment, so decisions about duration, future care, and maintenance strategies should be discussed with the prescribing team.

Side effects and monitoring

The most common side effects of Wegovy affect the digestive system. They are often most noticeable while the dose is being increased, though some people experience symptoms later or have few side effects.

Nausea, vomiting, diarrhea, constipation, or abdominal discomfort
Headache or fatigue
Reflux, bloating, or reduced appetite

Less commonly, more serious problems can occur. Severe or persistent abdominal pain, especially with vomiting, needs prompt medical advice because it could indicate a serious condition such as pancreatitis. Gallbladder problems, dehydration, and changes in blood sugar may also need attention. Seek urgent care for severe symptoms, and tell your prescriber about all medicines and relevant health conditions before starting.

Monitoring may include checking weight, side effects, dose tolerance, blood pressure, and relevant health markers. Your https://smoothdecorator.com/is-social-media-semaglutide-ever-safe/ team may also review nutrition, hydration, physical activity, and whether treatment is delivering meaningful benefit. People with diabetes who use medicines that can cause low blood sugar may need additional advice from their clinician.

Wegovy is not appropriate during pregnancy. Tell your prescriber if you are pregnant, planning a pregnancy, or breastfeeding. Follow current product information and medical advice about when to stop treatment before trying to conceive.

Be cautious about online offers

Search results, online marketplaces, and social media channels may feature weight-loss injections or claims about easy access. These are not substitutes for a clinical assessment. Counterfeit, improperly stored, or unlicensed medicines can pose serious risks, and online sellers may not provide appropriate follow-up.

Use a registered pharmacy and a qualified prescriber, and verify that the service is properly regulated in the UK. Avoid buying prescription medicines from informal sellers or sharing someone else’s medication. If an offer promises guaranteed results, bypasses screening, or pressures you to buy quickly, treat it as a warning sign.

How to find out if you might qualify

Speak with your GP or an appropriately qualified prescriber about your weight, health conditions, and treatment goals.
Ask whether you meet the NICE criteria and whether referral to a specialist weight-management service is available locally.
Discuss the potential benefits, side effects, monitoring plan, and what support will continue alongside medication.
If you do not qualify for NHS Wegovy, ask about other evidence-based options, including structured lifestyle support and other treatments that may be appropriate.

The bottom line

For NHS Wegovy in the UK, the usual NICE threshold is a BMI of at least 35 kg/m² plus here one or more weight-related conditions, with a possible lower-BMI route for people who meet specialist-service referral criteria. Lower BMI thresholds may apply to some ethnic groups. Private prescribing can follow different eligibility pathways, but still requires a proper clinical assessment.

Wegovy can support substantial weight loss for many people, but it is not a quick fix or a replacement for ongoing care. A clinician can help you understand whether treatment is suitable, how it would be monitored, and what realistic long-term support looks like.